[Hemorheologic effects of hydroxyethyl starch 200/0.5, dextran 40, oxypolygelatine and full electrolyte solution over 48 hours].
Four patient groups (n = 28 patients) received in a randomised clinical trial a single intravenous infusion of 500 ml of 10% dextran 40, 3.5% oxypolygelatine, 6% hydroxyethyl starch 200/0.5 or saline solution, respectively. The haemorheological parameters haematocrit, plasma viscosity and erythrocyte aggregation were followed up during 48 hours. In our study oxypolygelatine showed better rheological results than HAES 200/0.5. Dextran 40 especially increased the plasma viscosity and erythrocyte aggregation, so that we cannot recommend this plasma substituent for hypervolemic haemodilution.
Brehme
S
S
Abteilung für Kardiologie, Angiologie und Pulmologie, Humboldt-Universität zu Berlin, Charité.
Keysser
G
G
Turowski
A
A
Schmidt
H H
HH
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000628:therapy; D001809:Blood Viscosity / Q000187:drug effects*; D002545:Brain Ischemia / Q000628:therapy; D003911:Dextrans / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D005260:Female; D005780:Gelatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006400:Hematocrit; D006438:Hemodilution; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012212:Rheology; D012965:Sodium Chloride / Q000008:administration & dosage*
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D012965:Sodium Chloride; D005780:Gelatin; C002803:oxypolygelatine